Some people lose far more weight than others on GLP-1s like Wegovy. Here’s why.

Expected market reaction

Neutral Confidence 50% How confidence is read Horizon: Short term Impact: Low

Evidence

Source MarketWatch

Claim Some people lose far more weight than others on GLP-1s like Wegovy. Here’s why.

AI inference Neutral · 50%

Generated 2026-05-18 17:30

Analysed by Rule-Based Analysis not AI Methodology v1.0 Generated May 18, 2026 20:30

Technical identifiers

Emerging research shows there are ‘super-responders’ to GLP-1 drugs, and others who don’t respond at all.

Original article published by MarketWatch on May 18, 2026. Analysis and insights provided by AnalystMarkets AI.

Rule-Based Analysis · 38.9% correct across 475 scored calls on equities See the full record